The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?

QR Code

The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?

When evaluating the effect of therapy for malignant neoplasms with inhibitors of CTLA-4, PD-1 and PD-L1, the phenomenon of pseudoprogression may occur. Pseudoprogression is an increase in the volume of tumor tissue due to immunocompetent cells (lymphocytes, macrophages) mobilized into the tumor focu...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Vladislav O. Sarzhevskiy, Vladimir Ia. Melnichenko, Irina V. Panshina, Nikita E. Mochkin, Vladimir S. Bogatyrov, Maria M. Borshevetskaya, Elena G. Smirnova, Anna E. Bannikova, Anastasia A. Samoylova, Aysel A. Mamedova, Anatolij A. Rukavitsin, Sergei S. Vasilev, Oleg Iu. Bronov
Format:	article
Langue:	RU
Publié:	IP Habib O.N. 2021
Sujets:	immunotherapy pseudoprogression ctla-4 pd-1 pd-l1 inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/087c99ed4f454995bde9965434ae6e7f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
par: Virginia Liberini, et autres
Publié: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
par: Denis I. Yudin, et autres
Publié: (2021)

Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy
par: Chi Yan, et autres
Publié: (2021)

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma
par: Yan Li, et autres
Publié: (2021)

Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts
par: Yoshihide Suzuki, et autres
Publié: (2021)

Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
par: Pei-Yi Chu, et autres
Publié: (2021)

INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
par: I. O. Chikileva, et autres
Publié: (2019)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
par: Melissa L. Bastacky, et autres
Publié: (2021)

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries
par: Maria V. Deligiorgi, et autres
Publié: (2021)

Advances in Pancreatic Ductal Adenocarcinoma Treatment
par: Eric M. Anderson, et autres
Publié: (2021)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)

High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury
par: Dong L, et autres
Publié: (2021)

New Insights into the Role of PD-1 and Its Ligands in Allergic Disease
par: Miguel Angel Galván Morales, et autres
Publié: (2021)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021)

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
par: Xin Cai, et autres
Publié: (2021)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
par: Chang-Jin Jung, et autres
Publié: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
par: Otgontuya Ganbaatar, et autres
Publié: (2021)

Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
par: Kurtis M. Host, et autres
Publié: (2017)

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers
par: Yasuhito Mihashi, et autres
Publié: (2021)

Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review
par: María Rodríguez Plá, et autres
Publié: (2021)

Immunotherapeutic Advances for NSCLC
par: Massafra M, et autres
Publié: (2021)

NHC Polymeric Particles Obtained by Self-Assembly and Click Approach of Calix[4]Arene Amphiphiles as Support for Catalytically Active Pd Nanoclusters
par: Vladimir Burilov, et autres
Publié: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
par: Laura Jimbu, et autres
Publié: (2021)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
par: Lai CY, et autres
Publié: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
par: Zou W, et autres
Publié: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
par: Miao Wang, et autres
Publié: (2021)

Editorial: Volume 47 Issue 2
par: Sawsen Lakhal, et autres
Publié: (2021)

PREPARATION OF PALLADIUM THIN FILMS AND THEIR USEFULNESS AS MODIFIED ELECTRODES
par: TEJOS,MARISOL, et autres
Publié: (2002)

Evaluación farmacocinética/farmacodinámica (PK/PD) de un esquema de administración oral de metronidazol en intervalo ampliado para el manejo de infecciones producidas por Bacteroides fragilis
par: Morales-León,Felipe, et autres
Publié: (2015)

Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies
par: Gkiala A, et autres
Publié: (2020)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
par: He Ba, et autres
Publié: (2021)

Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis
par: Yuanfang Xin, et autres
Publié: (2021)

Dose Optimization of Aditoprim-Sulfamethoxazole Combinations Against Trueperella pyogenes From Patients With Clinical Endometritis by Using Semi-mechanistic PK/PD Model
par: Muhammad Kashif Maan, et autres
Publié: (2021)

Frequency Resolved Partial Discharges Based on Spectral Pulse Counting
par: Anderson J. C. Sena, et autres
Publié: (2021)

Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells
par: Rosanna Di Tinco, et autres
Publié: (2021)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
par: Christina Polasky, et autres
Publié: (2021)

Colorectal Cancer Progression Is Potently Reduced by a Glucose-Free, High-Protein Diet: Comparison to Anti-EGFR Therapy
par: Kerstin Skibbe, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)